Anupam Rasayan ETFA milestone puts stock in focus 2026

Why Anupam Rasayan is in focus on June 12

Shares of Anupam Rasayan India are expected to be watched on Friday, June 12, after the company disclosed a manufacturing milestone linked to ETFA (Ethyl Trifluoroacetate). In a regulatory filing, the specialty chemicals company said it has commercialised ETFA production using its proprietary “process-by-design” continuous flow chemistry platform. The company also said this achievement makes it the first globally to manufacture ETFA at a commercial scale using flow technology.

The update matters because it links a clearly defined product milestone to a platform claim, which investors often track in specialty chemicals where product qualification and scale-up can change the revenue mix over time. The company framed the announcement as part of its innovation journey, indicating that the continuous flow platform is central to how it plans to develop and scale certain chemistries.

What the company announced on ETFA commercialisation

Anupam Rasayan said it has achieved commercialisation of ETFA production via its continuous flow chemistry platform. The company described the platform as “process-by-design,” and positioned the commercial-scale flow-based manufacturing of ETFA as a global first.

Commenting on the achievement, Anand Desai, Managing Director of Anupam Rasayan, said the successful commercialisation of ETFA through the continuous flow chemistry platform is a significant milestone in the company’s innovation journey. The filing, as described in the provided text, emphasises the transition from development to commercial production rather than a pilot-only outcome.

ETFA market potential and end-use relevance

The company-linked note in the provided text pegged the market potential for ETFA at $100-600 million. ETFA is described as crucial for fluorinated compounds used in pharmaceuticals and life sciences. This context is important because fluorination-linked intermediates are often tied to regulated end markets, where customers value process control, consistency, and reliable scale.

The company did not disclose customer names, contract quantities, or a revenue contribution estimate from ETFA in the provided information. As a result, the commercial impact can only be described in terms of the stated market size and the company’s positioning statement on manufacturing capability.

What “continuous flow chemistry” signals for manufacturing

The announcement highlights “continuous flow” as the core manufacturing route for ETFA at scale. In specialty chemicals, flow processes are typically associated with improved control over reaction conditions and repeatability at scale, compared with certain batch processes. Here, Anupam Rasayan’s key claim is not just R&D capability but commercial-scale output using flow technology.

The company’s statement that it is the first globally to commercialise ETFA at scale using flow technology is a strong positioning claim. However, the provided text does not include third-party verification, competitor comparisons, or certification details. Investors will likely watch for further disclosures that connect ETFA commercialisation to long-term supply arrangements or repeat orders.

Stock performance: multibagger run since February 2025

The provided text says Anupam Rasayan’s shares have trended upward since February 2025, closing most months thereafter in the green. Over that period, the stock reportedly rose from ₹632.40 per share to a latest closing price of ₹1,258, translating to a gain of nearly 100%. The stock also touched a record high of ₹1,415 during the rally.

It also states the rally helped the stock end 2025 with gains of 82%, described as its biggest annual surge since listing. For 2026 year-to-date, the same source notes the stock is down a modest 5% amid broader market swings.

Separate pricing snippets included in the provided text mention the stock at ₹1,371.50 as of 20 May 2026 (up 0.75% from ₹1,361.1). Another excerpt shows a different snapshot where the last traded price is ₹1,091.90 after a -0.25% move from ₹1,094.60. These reflect different market updates captured in the supplied material.

Operating footprint, order book, and capacity details mentioned

A separate summary in the provided text describes Anupam Rasayan as having a strong order book, citing LOIs and contracts worth ₹146,460 million across life science and specialty chemicals. The same summary says the company operates eight manufacturing facilities in India and the US with total capacity of 200,552 MT.

The company is described as headquartered in Surat, Gujarat, and founded in 1984. The provided narrative also characterises it as a specialty chemicals manufacturer with presence in life science chemicals spanning agrochemicals, personal care actives, and pharmaceutical intermediates.

Financial snapshots cited in the supplied material (with caveats)

One section in the provided text says revenue rose from approximately ₹8,970 million in FY22 to an estimated ₹14,200 million in FY26E. It also mentions a temporary net profit dip in FY24 tied to a global agrochemical destocking cycle, and an FY26E profit estimate of about ₹1,750 million.

Another portion cites a “record high” net sales figure of ₹7,314.0 million and a latest-quarter PAT of ₹443.9 million, alongside a 43.8% increase versus the previous four-quarter average. Valuation metrics in the supplied content vary, with one table showing a P/E of 38x while another line states a P/E of 102.79 (against an industry average of 32.19). Because these figures come from different excerpts within the provided text, they should be read as multiple referenced snapshots rather than a single reconciled dataset.

US acquisition reference: Jayhawk Fine Chemicals

The supplied material also references an acquisition plan for US-based Jayhawk Fine Chemicals for $150 million, and notes an enterprise value of $134 million because of $16 million cash at Jayhawk. It further mentions that the transaction is described as EPS accretive, with combined revenue of $143 million and expected EBITDA of $11 million.

The same excerpt says Anupam Rasayan plans to invest $10 million through a wholly owned subsidiary, with $110 million coming from an investment company that would hold class B shares without voting rights, and that the investment company’s name was not final at the time.

Key facts table

Company contact details included in the supplied text

The provided material lists the company’s address as 1101 to 1107, 11th Floor, Icon Rio, Behind Icon Business Centre, Dumas Road, Piplod, Surat, Gujarat, 395007. It lists the investor email as investors@anupamrasayan.com, telephone number 0261-2398991-95, and fax number 0261-2398996.

What investors may watch next

The June 12 focus is tied to whether ETFA commercialisation progresses from a platform milestone to sustained supply, repeat customer orders, and broader product pipeline outcomes. The company has already framed the development as an innovation milestone and a global-first positioning claim at commercial scale.

Further regulatory disclosures, customer qualification updates, or segment-level commentary would be key to connecting the manufacturing achievement to measurable financial contribution. For now, the news flow is centred on the stated commercialisation and the company’s claim of being first to scale ETFA via flow technology.